This is a close look at Biocon Ltd. (BIOCON), covering the financials, the valuation picture, and who owns the stock.
Biocon Revenue Trend
Biocon Ltd. closed FY2026 with revenue of ₹16,927 Cr. That's up 10.9% from the ₹15,262 Cr it posted in FY2025.
Over a 10-year stretch, revenue climbed from ₹3,485 Cr to ₹16,927 Cr, a 17.1% CAGR. That pace of compounding is what sets the growth names apart.
With a ₹16,927 Cr revenue base, Biocon Ltd. ranks among the major names in the Indian pharmaceuticals sector.
Biocon Ltd. has now posted revenue growth for 10 consecutive years, a sustained trend rather than a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹16,927 Cr | +10.9% |
| FY2025 | ₹15,262 Cr | +3.4% |
| FY2024 | ₹14,756 Cr | +32.1% |
| FY2023 | ₹11,174 Cr | +36.5% |
| FY2022 | ₹8,184 Cr | — |
View Biocon Ltd.'s full 10-year revenue trend with CAGR analysis →
Biocon Profitability
On earnings, Biocon Ltd. posted ₹369 Cr for FY2026, a 74.2% drop from ₹1,429 Cr in FY2025.
Net margin slid from 9.4% to 2.2% in FY2026, a sign that costs outpaced revenue growth.
Diluted EPS tells a similar story: ₹2.82 in FY2026, down from ₹8.46.
Is Biocon Undervalued
Shares of Biocon Ltd. are currently changing hands at ₹427.00.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Biocon Shareholding Pattern
Promoter holding has slipped from 54.5% to 44.7%, a shift worth watching.
Foreign institutional ownership sits at 8.2%, up from 6.6% a year earlier.
Domestic institutions hold 23.4%, up from 22.1% in the year-ago quarter.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 44.7% | 8.2% | 23.4% | 23.7% |
| Mar 2026 | 44.9% | 7.5% | 24.1% | 23.4% |
| Dec 2025 | 54.5% | 7.4% | 21.7% | 16.3% |
| Sep 2025 | 54.5% | 6.6% | 22.1% | 16.7% |
Track quarterly shareholding changes for Biocon Ltd. →
Biocon Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹636.51B at the end of FY2026, up 8.3% from ₹587.97B a year earlier.
Intangibles & Goodwill is the largest block at 45.3%, followed by Property, Plant & Equipment at 22.1% and Inventories at 9.6%.
Equity makes up 57.5% of liabilities and equity, with debt at 24.2% and operating liabilities at 18.2%. Over the year, debt is down 15.9% and equity is up 32.1%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 31.06B |
| Receivables | 59.87B |
| Inventories | 60.86B |
| Property, Plant & Equipment | 140.86B |
| Investments | 11.32B |
| Intangibles & Goodwill | 288.09B |
| Other Assets | 44.45B |
| Category | Value |
|---|---|
| Equity | 366.22B |
| Short-term Debt | 41.51B |
| Long-term Debt | 112.83B |
| Trade Payables | 67.72B |
| Other Liabilities | 48.23B |
Biocon Investment Snapshot
The bottom line on Biocon Ltd. (BIOCON), based on the latest available financials.
FY2026 revenue came in at ₹16,927 Cr, up 10.9% year-over-year.
Revenue has compounded at 17.1% annually over the past 10 years.
The company remains profitable, with a net margin of 2.2% and net income of ₹369 Cr.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Biocon Ltd..